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Background: JAK2V617F, a gain-of-function mutant form of tyrosine kinase JAK2, is found in the majority of
patients with Ph- myeloproliferative neoplasms (MPNs), a group of chronic hematological diseases that often lead
to acute leukemia. The current study is intended to find other gene mutations that collaborate with JAK2V617F to
cause leukemic transformation.
Methods: Total RNA and genomic DNA were isolated from two JAK2V617F-positive cell lines, namely,
erythroleukemic HEL and megakaryoblastic leukemic SET-2 cells. Candidate genes were amplified by PCR and
further sequenced.
Results: Homozygous mutations of the TP53 gene which encodes tumor suppressor p53 were found in HEL and
SET-2 cells. While HEL cells, which have homozygous JAK2V617F, contain a rare M133K p53 mutation, SET-2 cells,
which have a heterozygous JAK2V617F mutation, contain a common R248W p53 alteration. Western blot analyses
revealed high levels of p53 expression in both cells. M133K and R248W are located in the DNA binding domain of
p53. Structural analyses revealed that they potentially disrupt the interaction of p53 with DNA, thereby causing loss
of p53 function.
Conclusions: JAK2V617F and p53 mutations coexist in leukemia cells. We believe that JAK2V617F is able to drive
leukemic transformation when the function of tumor suppressor p53 is lost. The interplay of JAK2V617F with p53
may affect the progression of MPNs.
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Ph- myeloproliferative neoplasms (MPNs) are clonal
hematopoietic disorders in which one or more myeloid
lineages are abnormally amplified. These diseases repre-
sent a group of chronic conditions including polycythemia
vera (PV), essential thrombocythemia (ET), and primary
myelofibrosis (PMF) [1]. MPNs mainly affect older people
with an average age of onset of 55 years. Complications
associated with MPNs include development of acute
leukemia as well as thrombosis, hemorrhage, and myeloid
metaplasia. The major molecular lesion in these diseases* Correspondence: Joe-zhao@ouhsc.edu
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reproduction in any medium, provided the oris JAK2V617F, which occurs in over 90% of PV and over
50% of ET and PMF [1,2]. JAK2V617F has enhanced tyro-
sine kinase activity, and it causes constitutive activation of
down-stream signal transducers when expressed in cells
[3]. Studies have demonstrated that transgenic expression
or knock-in of JAK2V617F in mice causes MPN-like phe-
notypes [4,5]. However, whether or not JAK2V617F is able
to drive leukemic transformation is not known.
Malignant transformation usually involves a gain-of-
function mutation of oncogenes and a loss-of-function
mutation of tumor suppressor genes. Among various
tumor suppressors, p53, which is encoded by the TP53
gene, has been extensively studied [6-8]. TP53 is
mutated or inactivated in over 60% of cancers. Normal
p53 suppresses malignant transformation by controlling
cell cycle progression, ensuring the fidelity of DNAtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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apoptosis in response to potentially deleterious events.
Interestingly, mutations of p53 are the most common in
solid tumors but relatively rare in blood cell malignan-
cies such as leukemia [7,9]. In this study, we investigated
the mutation status of p53 in two JAK2V617F-positive
leukemic cell lines. We found mutations of p53 in both
cells. One cell line bears a rare M133K mutation, while
the other contains a R248W alteration frequently found
in other tumors.
Results and discussion
Identification of p53 mutations in HEL and SET-2 cells
The constitutive activation nature of JAK2V617F makes
it a potential oncoprotein. To identify other gene muta-
tions that collaborate with JAK2V617F to drive leukemia
cell transformation, we employed two well-studied
leukemia cell lines, HEL and SET2, which are known to
contain JAK2V617F [10]. HEL (ATCC no. TIB-180) was
derived from an erythroleukemia patient [11], and SET-2
(DSMZ no. ACC 608) cells were established from an ET
patient at megakaryoblastic leukemic transformation
[12]. To investigate the mutation status of p53, we iso-
lated total RNA from the cells. Following reverse tran-
scription, the entire coding sequence of p53 was
amplified by PCR. Complete DNA sequencing analyses
revealed two distinct gene mutations in HEL and SET-2
cells (Figure 1). In HEL cells, the mutation is a T-to-A
transversion at position 398 of p53 cDNA, resulting in
an M-to-K substitution at amino acid residue 133 of theFigure 1 Identification of p53 mutation in HEL and SET-2 cells. The en
PCR from total RNAs isolated from HEL and SET2 cells together with a norm
mutation sites are indicated by arrows, and the associated changes in codo
HEL and SET2 cells are homozygous. DNA sequencing was also performedp53 protein. In SET-2 cells, the mutation is a 742C-to-T
transition at the DNA level resulting in a R248W
replacement at the protein level. Note that both muta-
tions are homozygous. We also verified the mutations by
amplifying genomic DNAs. The p53 mutations are found
in exon 5 and 7 of the TP53 genes in HEL and SET-2
cells, respectively. DNA sequencing analyses of PCR
products containing the correspondent exons revealed
homozygous mutations of p53 at the gDNA level (data
not shown). This indicates the homozygosity is likely
caused by mitotic homologous recombination rather
than gene silencing at the epigenetic level.
Protein expression levels of p53 in HEL and SET-2
cells were revealed by Western blot analyses (Figure 2).
Robust expressions of p53 were found in both cells as in
T cell lymphoma Karpas 299 cells which contain an
R273C mutation [7]. In contrast, p53 is absent in pro-
myelocytic leukaemia HL-60 cells which are known to
contain a TP53 gene deletion [7]. Likewise, expression of
p53 was hardly detectable in white blood cells from a
normal blood sample. These results support the notion
that M133K and R248W are loss-of-function mutants.
The expression level of normal p53 is kept low through
a continuous degradation mediated by MDM2, which is
itself a product of p53-activated gene expression, while
mutant p53 proteins which lose transcription activity do
not induce MDM2 and are thus able to accumulate at
very high concentrations [6-9].
We then verified the mutation status of JAK2 in HEL
and SET-2 cells used in our study. The presence oftire coding sequence of p53 was amplified by reverse transcription
al white blood cell sample for comparison. The positions of the
ns and amino acids are shown. Note that the p53 mutations found in
from the reverse direction with consistent results (not shown).
Figure 2 Expression levels of p53 in HEL and SET-2 cells. Whole
cell extracts of HEL, SET-2, Karpas 299, HL-60, and total normal white
blood cells were subjected to Western blot analyses with a
pantropic anti-p53 (Ab-2) antibody. Protein loadings were revealed
by an antibody against glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). Note that p53 in Karpas 299 cells runs slightly faster on the
gel.
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allele-specific PCR technique [13] (data not shown). We
further amplified a DNA fragment covering the exon 14
of JAK2 by PCR with genomic DNA as templates. DNA
sequencing analyses revealed a homozygous mutation of
JAK2 in HEL cells and a heterozygous JAK2 mutation in
SET-2 cells (Figure 3). To see if both mutant and wild
type alleles are expressed in SET-2 cells, the full-length
coding sequence of JAK2 was amplified from total RNAFigure 3 Verification of the presence of JAK2V617F in HEL and SET-2
cDNA were amplified by PCR from genomic DNAs and reverse-transcribed
from the reverse direction. Positions of the V617F mutation sites are indica
SET2 cells contain a heterozygous mutation at both genomic DNA and cD
direction with consistent results (not shown).by reverse transcription PCR. Sequencing of the RT-PCR
products demonstrated heterozygous JAK2 mutation, in-
dicating expression of both wild and mutant alleles in
SET-2 cells (Figure 3). DNA sequencing data also
revealed the predominant presence of JAK2V617F in
SET-2 cells. By using a real time PCR method previously
described [14], we determined that the ratio of
JAK2V617F to JAK2 is approximately 6:1 in SET 2 cells
at both the genomic and cDNA levels. Apparently, mu-
tation of JAK2 in SET-2 is also accompanied by gene
amplification of the mutant allele. It should be noted
that SET-2 cells were derived from an ET patient. It is
generally believed that ET patients usually bear a hetero-
zygous JAK2 mutation while PV patients mostly contain
homozygous JAK2V617F. Our data suggest that in the
heterozygous cases, the ratio of JAK2 and JAK2V617F
may not be necessarily equal.
Structural analysis of p53 mutants found in HEL and SET-
2 cells
We thus identified two distinct p53 mutations in
JAK2V617F-positive HEL and SET-2 cells. While the
M133K mutation identified in HEL cells is rare, R248W
found in SET-2 cells is one of the most frequently
mutated residues of p53 in human cancers [7]. Accord-
ing to the IARC TP53 database (Version R15, November
2010, see ref. 7), M133K has been found as a somatic
mutation in 20 tumors, whereas R248W has been
reported as a somatic mutation in 733 tumors and as a
germline mutation in 18 families with Li-Fraumeni syn-
dromes. The functional consequence of R248Wcells. DNA fragments containing JAK2 exon 14 and full-length JAK2
single-strand cDNAs, respectively. DNA sequencing was performed
ted by arrows. Note that HEL cells carry a homozygous mutation while
NA levels. DNA sequencing was also performed from the forward
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sentially no reported study on the M133K mutant [7].
Both M133K and R248W are located in the DNA bind-
ing domain of the p53 molecules. Based on the crystal
structure of the DNA binding domain of p53 in complex
with DNA [15], structure analyses predict that both
mutations have deleterious effects on p53 function
(Figure 4). The R248 residue forms loop 3 of the p53
core structure and reaches into the minor groove of
DNA. It presumably plays a critical role in DNA bind-
ing, and mutation of this basic residue to a bulky aro-
matic tryptophan residue should have detrimental effects
on binding of p53 with DNA. The M133 residue, on the
other hand, is located in the S2' strand and is buried in
the loop-sheet-helix motif. This motif makes up the
major DNA binding surface of the p53 molecule. Al-
though M133 does not directly interact with DNA, its
mutation to a basic arginine residue may significantly
alter the conformation of the entire loop-sheet-helix
motif, thereby disrupting DNA binding.
The mutation rate of p53 in leukemia overall is very
low, but it is much higher in acute myeloid leukemiaFigure 4 Potential deleterious effects of the M133K and R248W muta
schematic diagram of p53 structure with the relative positions of the M133
the crystal structure of the DNA binding domain of p53 in complex with D
and sticks, while the rest of the amino acid residues are represented in thewith a complex aberrant karyotype [7,9,16]. Interestingly,
both HEL and SET-2 cells display an abnormal karyo-
type with selective JAK2 chromosomal amplification and
concomitant deletion of the residual homolog [10]. In-
deed, the 6:1 JAK2V617F/JAK2 ratio found in our
current study suggests amplification of the mutant JAK2
allele. In addition, earlier studies identified p53 muta-
tions in about half of MPN patients in blast crisis
[17,18], suggesting inactivation of p53 may be relatively
frequent in blastic transformation of MPNs and is
required for the process. These studies were conducted
before the discovery of JAK2V617F but included analysis
of NRAS and KRAS which were found intact. Our
current study demonstrates coexistence of JAK2V617F
and mutations of p53 in leukemia cells. This provides
evidence that JAK2V617F likely drives leukemic trans-
formation when p53 function is lost. We also believe
that the dependence of MPN phenotypes on aging may
be related to decreasing activity of p53. Among various
factors affecting aging, p53 is most extensively studied
[19-21]. In fact, loss of p53 activity is considered an
aging process. Besides p53 mutations, p53 function cantions on structure and function of p53. The upper panel shows a
K and R248W mutation sites indicated. The lower panel demonstrates
NA. Side chains for M133 (green) and R248 (red) are shown as balls
backbone by ribbons.
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recent study demonstrated that JAK2V617F negatively
regulates p53 stabilization by enhancing MDM2 via La
expression in MPNs [22]. Our data further support the
notion that JAK2V617F interacts with p53 to promote
progression of MPNs. Therefore, inhibiting JAK2V617F
and maintaining p53 function are of utmost therapeutic
importance.
Conclusions
We identified the coexistence of JAK2V617F and p53
mutations in leukemia cells. This suggests that
JAK2V617F is able to drive leukemic transformation when
the tumor suppressor function of p53 is lost. Decreased
p53 activity as a consequence of aging may also affect the
progression of MPNs. Understanding the interplay of
JAK2V617F and p53 should have major implications for
prevention and treatment of the diseases.
Methods
Cells and DNAs
HEL (ATCC no. TIB-180) and SET-2 (DSMZ no. ACC
608) cell lines were purchased from American Type Cul-
ture Collection (ATCC) and German Collection of
Microorganisms and Cell Cultures (DSMZ), respectively.
The cells were maintained in RPMI 1640 medium sup-
plemented with 20% heat-inactivated fetal bovine serum.
White blood cells were isolated from de-identified nor-
mal blood samples upon lysis of red blood cells. Total
RNAs were isolated from cells by using the Trizol re-
agent (Invitrogen), and single strand cDNAs were
synthesized with random primers by using a reverse
transcription kit from Promega. Genomic DNAs were
purified by using the phenol/chloroform method after
proteinase K digestion of whole cell lysates.
PCR and sequencing analysis
PCR was run with high fidelity Phusion DNA polymerase.
The entire coding regions of p53 and JAK2 were amplified
from single strand cDNAs. The PCR primers used were
GCCAGACTGCCTTCCGGGTCACT (forward) and
AGAGATGGGGGTGGGAGGCTGTC (reverse) for p53,
and TGCATGGGAATGGCCTGCCTTAC (forward) and
CTTTCATCCAGCCATGTTATCCCTTA (reverse) for
JAK2. Genomic DNA surrounding the entire exon 14 of
the JAK2 gene was amplified by PCR from genomic DNAs
with primers GATCTCCATATTCCAGGCTTACACA
(forward) and TATTGTTTGGGCATTGTAACCTTCT
(reverse). The PCR products were gel-purified and sub-
jected to DNA sequencing analyses by using an ABI 3730
capillary sequencer at the core facility of University of
Oklahoma Health Sciences Center. DNA sequencings
were performed from both forward and reserve directions.
To determine the ratio of JAK2 and JAK2V617F at thegenomic or cDNA level, real time PCR analyses were per-
formed as previously described [14], except that purified
plasmid DNAs were used as standards [13].
Western blot analyses
Cells were extracted in SDS gel sample buffer. Upon
separation on 10% SDS gels and transferring to PVDF
membranes, proteins were probed with antibodies
against p53 and glyceraldehyde 3-phosphate dehydro-
genase followed by a horseradish peroxidase-conjugated
secondary antibody. Detection by the electrochemilumi-
nescence method and capture of immunoblot images
were carried out by using FluorChem SP imaging system
from Alpha Innotech as previously described [23].
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